IFP Advisors’s Inhibikase Therapeutics IKT Stock Holding History

IFP Advisors’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2	Sell	1 -22	-96%	-$50	﹤0.01%	5212
2026 Q2	$47	Buy	23 +20	+667%	+$36	﹤0.01%	5025
2026 Q1	$5	Buy	+3	New	+$5	﹤0.01%	4994

Other funds holding IKT

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

IFP Advisors's IKT Position: Q3 2026 in Review

IFP Advisors reduced its Inhibikase Therapeutics (IKT) stake by 96% in Q3 2026, selling an estimated $50 and leaving 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #5212.

IFP Advisors first reported a position in IKT in Q1 2026 and has held it in 3 quarters since. The position peaked at $47 in Q2 2026. 8 funds tracked by Wall St. Rank hold IKT as of Q3 2026.

IFP Advisors held 1 share of Inhibikase Therapeutics worth $2 as of Q3 2026.
IFP Advisors sold 22 Inhibikase Therapeutics shares in Q3 2026, an estimated $50.
Inhibikase Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #5212 holding.
IFP Advisors first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 3 quarters since.
IFP Advisors's Inhibikase Therapeutics position peaked at $47 in Q2 2026.
8 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.